The Scientific World Journal / 2014 / Article / Tab 1

Clinical Study

Oxidant-Antioxidant Balance during On-Pump Coronary Artery Bypass Grafting

Table 1

Demographic data of groups.

Whole patients ()Group 1 ()Group 2 () value*

Age, year62.87 ± 10.31063.64 ± 8.58262.17 ± 12.0210.741
Male, (%)17 (73.9%)8 (72.7%)9 (75.0%)0.901
BSA (m2)1.838 ± 0.1751.848 ± 0.1931.828 ± 0.1650.793
Urea (mg/dL)38.13 ± 10.38535.91 ± 13.21740.17 ± 6.8870.338
Creatinine (mg/dL)0.939 ± 0.2820.918 ± 0.2990.958 ± 0.2780.742
ALT (U/L)28.57 ± 18.57122.64 ± 10.85634.00 ± 22.700 0.147
AST (U/L)32.96 ± 18.82635.09 ± 22.17031.00 ± 15.9150.614
ACE inhibitors, (%)11 (47.8%)4 (36.4%)7 (58.3%)0.292
Calcium antagonists, (%)1 (4.3%)0 (0%)1 (8.3%)0.328
Beta blockers, (%)4 (17.4%)2 (18.2%)2 (16.7%)0.924
Nitrates, (%)5 (21.7%)2 (18.2%)3 (25.0%)0.692
HT, (%)17 (73.9%)7 (63.6%)10 (83.3%)0.283
DM, (%)5 (21.7%)2 (18.2%)3 (25.0%)0.692
COPD, (%)3 (13.0%)2 (18.2%)1 (8.3%)0.484
PAD, (%)2 (8.7%)1 (9.1%)1 (8.3%)0.949
CVD, (%)1 (4.3%)0 (0%)1 (8.3%)0.328
Smoking, (%)7 (30.4%)2 (18.2%)5 (41.7%)0.221
Alcohol, (%)1 (4.5%)1 (9.1%)0 (0%)0.306
CCS class2.26 ± 0.4492.36 ± 0.5052.17 ± 0.3890.304
LVEF53.48 ± 9.22452.27 ± 8.47554.58 ± 10.1040.561
LMCAD1 (4.3%)0 (0%)1 (8.3%)0.328

*Comparison of group 1 and group 2.
ACE: angiotensin converting enzyme, ALT: alanine aminotransferase, AST: aspartate aminotransferase, BSA: body surface area, CCS: Canadian Cardiovascular Society, COPD: chronic obstructive pulmonary disease, CVD: cerebrovascular disease, DM: diabetes mellitus, HT: hypertension, LMCAD: left main coronary artery disease, LVEF: left ventricular ejection fraction, and PAD: peripheral arterial disease.